FDA to review genetically engineered farm animals
By AP,
Associated Press
| 09. 18. 2008
Super Chicken strutted a step closer to the dinner table Thursday. The government said it will start considering proposals to sell genetically engineered animals as food, a move that could lead to faster growing fish, cattle that can resist mad cow disease, or perhaps heart-healthier eggs laid by a new breed of chicken.
The Food and Drug Administration issued a proposed legal framework for how it would resolve such questions as whether the altered animals are safe for human consumption and pose no serious environmental risks. FDA officials said they are focusing on animals that will be used as food, or to produce medications that would then be consumed by people or other animals. The agency is not interested in reviewing genetically engineered mice already widely used in lab experiments.
"Genetic engineering of animals is here and has been here for some time, " said Larisa Rudenko, a science policy adviser with the FDA's veterinary medicine center. "We intend to provide a rigorous, risk-based regulatory path for developers to follow to help ensure public health and the health of animals."...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...